Recombinant AAV Capsid Protein Ratios in Baculovirus Systems
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The baculovirus-insect cell system for producing recombinant adeno-associated virus (rAAV) faces challenges with reduced VP1 content and potency compared to mammalian cell systems, necessitating improvements in capsid protein ratio and yield for industrial-scale production.
Innovation Solution
Modifications to the AAV cap gene in the baculoviral helper construct, including specific mutations in VP1, VP2, and AAP proteins, are introduced to enhance capsid protein stability and enzymatic activity, leading to improved rAAV production yields and potency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the baculovirus-insect cell system is used for rAAV production, then production scalability and industrial applicability are improved, but capsid protein ratio (VP1:VP2:VP3) and potency deteriorate
Solution Approach 1:
The patent applies parameter changes by modifying the cap gene sequence to alter the expression parameters of capsid proteins. Specifically, the invention uses a cap gene from AAV9 or introduces mutations into AAV6 cap gene to change the expression levels of VP1, VP2, and VP3 proteins, thereby achieving an improved capsid protein ratio (VP1:VP2:VP3 of 1:1:10 to 1:1:30) in insect cells while maintaining production scalability
Solution Approach 2:
The patent applies local quality by introducing specific mutations at particular positions in the cap gene sequence. The invention identifies and modifies specific codons in the cap gene to locally alter the expression properties of capsid proteins, enabling improved VP1 content and potency at specific locations in the protein sequence without affecting overall production scalability
2Ease of manufacture
If standard AAV cap gene is used in baculoviral helper construct, then production process simplicity is maintained, but rAAV potency and VP1 content are reduced
Solution Approach 1:
The patent changes the genetic parameters of the cap gene to improve potency. By using AAV9 cap gene or introducing specific mutations (such as those at positions 157, 162, 164, 179, 188, 194, 196, 197, 200, and 201) into AAV6 cap gene, the invention alters the expression parameters to increase VP1 content and potency while maintaining the simplicity of the baculovirus-insect cell production process
3Reliability
If cap gene mutations are introduced to improve VP1 content, then potency is improved, but capsid protein stability may be affected
Solution Approach 1:
The patent carefully selects parameter changes in the cap gene that improve potency without compromising stability. The specific mutations introduced (such as those in the VP1:VP2:VP3 ratio control regions) are chosen to optimize expression levels while maintaining the structural integrity and stability of the capsid proteins, achieving both improved potency and maintained stability
Data Source
AI summary
Provided herein are nucleic acid constructs, host insect cells, and methods for producing recombinant AAV capsids with high potency at high yield.